Targeting Long Non-Coding RNA TTN-AS1 Suppresses Bladder Cancer Progression

Huiyuan Xiao1†, Wen Huang1†, Yanlei Li2, Rongxin Zhang3 and Long Yang1*

1Department of Urology, Tianjin Medical University General Hospital, Tianjin, China, 2Department of Pathology, Tianjin Medical University, Tianjin, China, 3Department of Radiotherapy, Tianjin Medical University General Hospital, Tianjin, China

Background: To explore the biological and clinical effects of titin-antisense RNA1 (TTN-AS1) in bladder cancer (BC) and the association between TTN-AS1 and activating transcription factor 2 (ATF2) in BC.

Methods: The Kaplan–Meier method was performed to analyze the association between the expression of TTN-AS1 and prognosis of BC patients from TCGA data set and our institution. Quantitative real-time PCR (RT-PCR) was conducted to explore the expression of TTN-AS1 between the patients who underwent TURBT and Re-TURBT. MTT, colony formation, and tumor formation assays were conducted to evaluate the effect of TTN-AS1 on the ability of proliferation in BC cell lines. Transwell assay was performed to evaluate the effect of TTN-AS1 on the ability of invasion in BC cell lines. Bioinformatics and immunohistochemical staining was used to identify the relationship between TTN-AS1 and ATF2.

Results: The higher expression of TTN-AS1 was related to poorer disease-free survival (DFS) in patients with BC. The expression of TTN-AS1 was higher in BC patients who underwent Re-TURBT compared with BC patients who underwent TURBT. Knocking down TTN-AS1 resulted in inhibiting the ability of proliferation and invasion of BC cells. ATF2 may serve as a downstream target of TTN-AS1 in BC, and the high expression of ATF2 is also related to adverse DFS.

Conclusion: Our study reveals that TTN-AS1 serves as an oncogene by activating ATF2 in BC. The findings suggest that TTN-AS1 may act as a novel therapeutic target for patients with BC.

Keywords: long non-coding RNA, bladder cancer, prognosis, oncogene, bioinformatics

INTRODUCTION

Bladder cancer (BC) is one of the most frequent urinary malignancies in males with high recurrence and poor prognosis (Torre et al., 2015; Siegel et al., 2019). As one of the lethal causes in patients, BC is still a major issue for public health. In patients with non-muscle-invasive BC (NMIBC), the tumor is confined to the mucosa or submucosa of the bladder wall. However, if the tumor invades the muscle layer, it is called muscular invasive BC (MIBC). If the patient with MIBC does not develop distant metastasis or invade adjacent tissues, the bladder and the tumor should be considered to be surgically removed (Hinsenveld et al., 2021). With deepening research, more and
more efforts have been made to find effective therapeutic targets against BC improving patient outcomes.

Long noncoding RNA (lncRNA), which is a subtype of RNA defined as transcripts >200 nt without protein-coding ability, is explored often and suggested to have a regulatory role in the development and progression of BC (Lv et al., 2017; Li et al., 2018; Quan et al., 2018; Zhang et al., 2019). A recent study shows that lncRNA NR2F1-AS1 could serve as an independent prognostic factor in BC, and the researchers established a genomic-related nomogram to predict the prognosis of BC (Peng et al., 2021).

In this study, we explore the relationship between ATF2 and lncRNA TTN-AS1 in vitro and in vivo. We also demonstrate that ATF2 and lncRNA TTN-AS1 plays a vital role in the progression of BC.

**MATERIALS AND METHODS**

**Ethical Approval for the Study Protocol**

This study was approved by the Ethics Committee of Tianjin Medical University General Hospital, Tianjin, China (No. KY2020K09). Written informed consent was obtained from all patients, and the study was conducted in accordance with the Declaration of Helsinki.

**Human Samples**

The bladder tissue specimens were surgical specimens from BC patients with complete clinicopathological data. BC tissues that were embedded in paraffin were acquired by transurethral resection of bladder tumor (TURBT) at the Tianjin Medical University General Hospital (n = 130). All patients did not receive chemotherapy and radiotherapy before surgery. The fresh paired BC tissues which were recurred (recurrence means that a patient who was diagnosed with BC for the first time has a new tumor in the bladder after undergoing TURBT surgery) were immediately stored in liquid nitrogen after TURBT (n = 6).

**Antibodies**

The antibodies used in this study are listed as follows: ATF2 (Abcam, ab239361, 1:250 dilution for IHC) and Ki67 (Abcam, ab15580, 1:1,000 dilution for IHC).

**Cell Lines and Cell Culture**

Human BC cell line T24 and 5,637 cells were purchased from the American Tissue Culture Collection (ATCC). T24 and 5,637 cells were incubated in RPMI 1640 (Gibco, Waltham, MA United States). All media were supplemented with 10% fetal bovine serum (Gibco, Waltham, MA United States). All experimental cell lines were cultured at 37°C containing 5% CO2.

**In vitro Transfection**

Transfection was performed using cells in the logarithmic growth phase. The cells are seeded into six-well plates at a density of 5 × 105 cells/well. After the cells grow to 60% of the area of each well, transfection is performed. The specific procedure was carried out with Lipofectamine 3,000 according to the manufacturer’s instructions (Invitrogen, Thermo Scientific, MA, United States). The shRNA targeting TTN-AS1 (shTTN-AS1) and the shRNA targeting scramble (shSCR) were obtained from Shanghai GenePharma Co., Ltd (Shanghai, China).

**Polymerase Chain Reaction**

Total RNA was extracted using Trizol and reverse transcribed into cDNA. Using the cDNA as a template, PCR was performed to detect the expression of TTN-AS1 using GAPDH as an internal reference. The primer sequences were as follows: TTN-AS1 forward primer, 5′- GCCAGGTAGTGGTGCAAGTTT-3′; reverse primer, 5′- GAGCCTGCAGGATGATGAAG-3′; GAPDH forward primer, 5′- GATTCCACCCCATGGCAAATT-3′; reverse primer, 5′-CTCCGGCTCCTGGGAAGATGGT-3′. Reaction bands were observed using gel electrophoresis.

**MTT Assay**

Weigh 0.5 g of MTT [3-(4,5)-dimethylthiazol(2,5)-diphenyltetrazolium bromide] order and dissolve it in 100 ml of PBS and pass the solution through a sterile filter membrane with a pore size of 0.22 μm to filter out bacteria in the solution. Add 100 μl of cell culture medium to each well of the 96-well plate and ensure that there are 2 × 103 cells in each well. Place the paved 96-well plate in a constant temperature cell incubator containing 5% CO2 at 37°C for culture. After a certain period of time, discard the medium in the well plate, add 100 μl of MTT solution to each experimental well and then place it in a cell culture incubator for 4 h. The supernatant was discarded again, and 150 μl of DMSO was added to each experimental well. Place the 96-well plate on a plate shaker and shake it slowly, and then place the solution to be checked in the microplate reader, measure the optical density at a wavelength of 570 nm, and record the optical density value.

**Colony Formation Assay**

When the cells are in the logarithmic growth phase, the BC cells were collected and cultured by a conventional cell culture method. When macroscopic colonies appeared in the Petri dish, the culture was terminated. Discard the supernatant, add 4% paraformaldehyde to fix the cells, and then stain the cells with GIMSA application staining solution. Slowly wash away the staining solution with running water and let the plate dry completely. Finally calculate the number of clones.
Invasion Transwell Assay
Take 200 µl of the cell suspension and add it to the Transwell chamber to ensure that each well contains \(1 \times 10^4\) cells. Perform cell culture in a conventional cell culture method. After 48 h, remove the chamber and discard the supernatant. Fix and stain the cells under the Transwell membrane; observe and count under a microscope.

In vivo Experiment
Male nude mice (8 weeks old, \(n = 10\)) were purchased from Beijing HFK Bioscience Co., Ltd (Beijing, China). Subcutaneous tumor growth assays were performed with T24 cell lines (\(1 \times 10^6\) T24 cells injected in each mouse). The tumor size was measured every 7 days with a Vernier calliper, and the volume change of the tumor was calculated. The tumors were harvested under standard, institutionally approved processes. The mass of each tumor was measured with an electronic balance. Tumor samples were paraffin-fixed and processed for immunohistochemical (IHC) analysis.

Immunohistochemistry
For IHC staining, paraffin-embedded tissue samples were deparaffinized, rehydrated, and incubated with primary antibodies (rabbit antihuman monoclonal antibody ATF2 antibody) overnight at 4°C. The secondary antibodies (goat antirabbit IgG) were incubated at room temperature for 1 h. The signals were examined under a microscope.

Statistical Analysis
Statistical significance was determined using two-tailed Student’s \(t\)-test or ANOVA for functional analysis. Survival curves were plotted using Kaplan–Meier survival plots and a log-rank test was used to test significance. All statistical analyses were performed using SPSS software and GraphPad Prism7. \(p < 0.05\) was considered statistically significant. \(p < 0.05\) was marked as *, \(p < 0.01\) was marked as **, \(p < 0.001\) was marked as ***, and no significant difference was expressed as n.s.

RESULTS
Highly Expressed IncRNA TTN-AS1 Is Correlated With BC Progression
LncRNA TTN-AS1 has been stated and functionally confirmed to be involved in a variety of cancer progressions (Chang et al., 2020; Feng et al., 2020; Lin et al., 2020; Miao et al., 2020; Qi and Li, 2020). Although the role of TTN-AS1 in BC is still poorly understood.
characterized. To investigate the clinical relevance of TTN-AS1 expression in BC, we retrieved public TCGA data sets from cBioPortal (Cerami et al., 2012; Gao et al., 2013) and evaluated TTN-AS1 expression in relation to disease-free survival (DFS) data as well as overall survival (OS) data on 322 BC patients. We found that BC patients with TTN-AS1 gene high expression had worse DFS (cutoff high expression: 60% of all patients; cutoff low expression: 40% of all patients).

**TABLE 1** | Clinicopathologic variables and TTN-AS1 expression in 130 bladder cancer patients.

| Variables                  | All n = 130 | Low n = 35 | High n = 95 | p value* |
|----------------------------|-------------|------------|-------------|----------|
| Age                        |             |            |             |          |
| <65                        | 61          | 16         | 45          | 0.87     |
| ≥65                        | 69          | 19         | 50          |          |
| Sex                        |             |            |             |          |
| Male                       | 54          | 14         | 40          | 0.83     |
| Female                     | 76          | 21         | 55          |          |
| Tumor stage                |             |            |             |          |
| T2                         | 60          | 25         | 35          | ≤0.01    |
| T3/T4                      | 70          | 10         | 60          |          |
| Tumor grade                |             |            |             |          |
| Low                        | 60          | 22         | 38          | 0.02     |
| High                       | 70          | 13         | 57          |          |
| Lymph node metastasis      |             |            |             |          |
| No                         | 50          | 20         | 30          | ≤0.01    |
| Yes                        | 80          | 15         | 65          |          |
| Vascular invasion          |             |            |             |          |
| No                         | 70          | 25         | 45          | 0.01     |
| Yes                        | 60          | 10         | 50          |          |

*p value was analyzed by Chi-square test; * indicates p < 0.05 with statistical significance; iPSA means initial PSA.

**FIGURE 2** | Knockdown of lncRNA TTN-AS1 inhibits the proliferation and invasion of BC cells in vitro. (A,B) The MTT assay was used to explore the proliferation of two BC cell lines (T24 and 5,637) after the knockdown of lncRNA TTN-AS1. The absorbance value was detected at a wavelength of 490 nm (* means: p < 0.05, ** means: p < 0.01). (C) Colony formation assays was conducted to detected the abilities of proliferation in two BC cell lines (T24 and 5,637) after knocking down lncRNA TTN-AS1 and the number of colonies was counted and plotted on a graph (*** means: p < 0.001). (D) Transwell invasion assays were conducted to detect the invasiveness of the BC cell lines (T24 and 5,637) after knockdown of lncRNA TTN-AS1, and the number of invaded cells was counted and plotted on a graph (*** means: p < 0.001).
(Figure 1A), and its expression has no prediction of OS (Figure 1B). Except that the DFS of BC patients from our institution was also analyzed. As shown in Figure 1C, the TTN-AS1 high expression group had an adverse DFS, which was coincident with the TCGA database. The association between TTN-AS1 expression and clinical characters in BC patients was also analyzed by using chi-square test. As shown in Table 1, the high TTN-AS1 expression was related with advanced tumor stage ($p \leq 0.01$), high tumor grade ($p = 0.02$), lymph node metastasis ($p \leq 0.01$) and vascular invasion ($p = 0.01$).

Given the association with BC progression of highly expressed lncRNA TTN-AS1, we performed PCR detection on TURBT and paired re-TURBT specimens ($n = 6$) collected in our hospital. PCR results suggest patients received re-TURBT with recurrence may be correlated with local increased expression of TTN-AS1 (Figure 1D). These results led us to propose the clinical association and oncogenic role of TTN-AS1 in BC.

**Silence of lncRNA TTN-AS1 Suppresses BC Cell Proliferation and Invasion**

To investigate whether lncRNA TTN-AS1 participates in BC growth, a loss of function assay was performed to evaluate T24 and 5,637 cell growth upon TTN-AS1 silencing. Knockdown of TTN-AS1 in T24 and 5,637 cell lines resulted in significant inhibition of cell growth (Figures 2A,B). Consistent with the results in Figures 2A,B, colony assays confirmed the inhibition of cell proliferation in T24 and 5,637 cells after TTN-AS1 knockdown (Figure 2C). Transwell assays demonstrate the significantly decreased abilities of invasion (Figure 2D).

**Targeting lncRNA TTN-AS1 Attenuates BC Growth in vivo**

To explore the potential of targeting lncRNA TTN-AS1 in BC, we employed lentiviral injection in T24 tumor xenografts. T24 cells were xenografted into 8-week-old immunocompromised severe combined immunodeficiency (SCID) mice ($n = 10$). The scramble set (shSCR) ($n = 5$) was injected with lentiviruses carrying control scramble shRNA, and the treatment set (shTTN-AS1) ($n = 5$) was injected with lentiviruses carrying lncRNA TTN-AS1 shRNA. Injections were carried out every 3 days for 3 weeks lncRNA TTN-AS1 knocked down during this long-term treatment period led to a significant suppression in the growth of the T24 tumors (Figures 3A–C). The efficiency of silence for TTN-AS1 was validated by PCR in the scramble set and treatment set of tumors (Figure 3D). These results support the potential preclinical significance of targeting lncRNA TTN-AS1 in BC therapy.

**ATF2 Acts as a Downstream Target of lncRNA TTN-AS1 in BC**

To explore the downstream of lncRNA TTN-AS1 in BC, we first evaluated its similar expression pattern genes upon the TCGA BC
data set by the GEPIA online tool (Tang et al., 2017). ATF2, a member of the AP1 transcription factor family, was listed as the top similar gene of TTN-AS1 (Hai and Curran, 1991; Shaulian and Karin, 2002). A previous study reveals that ATF2 protein is upregulated significantly in BC surgical specimens compared with normal urothelial tissues (Inoue et al., 2018). This study further shows that moderate/strong expression of ATF2 detected by IHC is correlated with poor prognosis of low-grade and muscle-invasive tumors (Inoue et al., 2018). To further investigate the expression relevance of lncRNA TTN-AS1 and ATF2 in BC specimens, we retrieved public TCGA data sets from cBioPortal (Cerami et al., 2012; Gao et al., 2013) and analyzed the two gene-expressed correlation coefficients. We found that these two gene-expressed levels were correlated significantly (Figure 4A). Then, we evaluated ATF2 expression in relation to DFS data as well as OS data on 322 BC patients. We found that BC patients with ATF2 gene high expression had worse DFS (cutoff high expression: 60% of all patients; cutoff low expression: 40% of all patients) (Figure 4B) although its expression has no prediction of OS (Figure 4C). To validate the downstream of lncRNA TTN-AS1, determination of ATF2 protein expression was performed by IHC in xenografts with silence of TTN-AS1 shown in Figure 3A. The results reveal that knockdown of lncRNA TTN-AS1 downregulated the expressed level of ATF2 and ki67 in our in vivo T24 tumor xenografts (Figure 4D).

**DISCUSSION**

lncRNA, the length of which was more than 200 nt, plays a crucial effect in modulating proliferation, invasion, and migration of various types of tumors, such as BC (Li et al., 2020a), renal cancer (Li et al., 2020b), thyroid cancer (Samimi et al., 2020), and so on. In recent years, more and more studies have found that lncRNA is abnormally expressed in pan cancer plays an important role in different biological activities, such as autophagy (Cao et al., 2020), epithelial-mesenchymal transition (Wan et al., 2020), cell proliferation (Zhang et al., 2020) and apoptosis (Lun et al., 2020). Numerous studies have pointed out that lncRNA plays a vital role in the carcinogenesis, drug resistance, and metastasis of BC. For
instance, lncRNA KCNQ1 opposite strand/antisense transcript 1 was found to be overexpressed in BC tissues compared with normal bladder tissues and can promote cell proliferation, migration, invasion, and apoptosis via modulating the miR-218–5p/HS3ST3B1 axis (Li et al., 2020a). Except that, Li et al. (2020b) demonstrated that overexpression of insulin-like growth factor binding protein 4-1 could activate the JAK/STAT pathway to promote BC cell proliferation, cell cycle, and cell apoptosis. More and more studies have explored that lncRNA TTN-AS1 have participated in carcinogenesis and tumor development and served as a potential therapeutic target in many types of tumors. For example, TTN-AS1 regulates the TTN-AS1/miR-195/cyclin D1 axis through sponge adsorption so as to promote tumor cell proliferation and modulate tumor cell cycle activities in clear cell renal cell carcinoma (Lin et al., 2020). In breast cancer, the abnormally high expression of TTN-AS1 promotes the proliferation, migration, and invasion of tumor cells by inhibiting mir-524 and promoting the expression level of RRM2 (Feng et al., 2020).

So far, no relevant research has pointed out the role of TTN-AS1 in the occurrence and progression of nonmuscular invasive BC. In this study, we found, for the first time, that TTN-AS1 is abnormally highly expressed in BC and is related to the poor prognosis of BLACA patients. In terms of mechanism, TTN-AS1 can promote the proliferation and invasion of tumor cells by regulating the expression of downstream factor ATF2. In short, we find that TTN-AS1 can exhibit the role of oncopgenes and serve as a therapeutic target for BC through in vitro experiments, in vivo experiments, and clinical data analysis.

LncRNA regulates tumor mechanisms in a variety of ways, including affecting the transcription of the upstream promoter region of the coding protein gene, mediating chromatin remodeling, histone modification, and changing the cellular localization of proteins, etc. (Chen et al., 2020). ATF2 is reported to play two roles in different types of tumors during tumor progression, namely, tumor-promoting genes and tumor-suppressor factors (Lopez-Bergami et al., 2010). In Inoue’s study, they found that ATF2 acted as an oncogene that promoted cell viability, migration, and invasion of BC via the AR signal pathway. Our study analyzes the survival information of BC patients in the TCGA database by bioinformatics and also finds that BC patients in the ATF2 high expression group had adverse DFS. Interestingly, we found that TTN-AS1 and ATF3 were correlated significantly via bioinformatics. Therefore, we propose the hypothesis that ATF2 may be a downstream factor of TTN-AS1 in BC. Furthermore, we used IHC to analyze the protein expression level of ATF2 in tumor tissues in both the knockdown TTN-AS1 and control groups. We find that, after knocking down TTN-AS1, the protein level of ATF2 was also significantly downregulated. Therefore, the oncogenic factor ATF2 of BC may be a potential downstream factor of TTN-AS1. TTN-AS1 promotes the proliferation and invasion of BC cells via inducing the expression of ATF2.

In summary, TTN-AS1 plays a role as a tumor-promoting factor in the progression of BC and can positively regulate the proliferation and invasion of BC cells by regulating the expression of ATF2. At the same time, TTN-AS1 is related to the poor prognosis of BC patients. Therefore, TTN-AS1 can be used as both a potential therapeutic target for Ponge and a predictor to evaluate the prognosis of patients with BC. In addition, this study contains the following shortcomings: the mechanism through which TTN-AS1 regulates the expression of its downstream factor ATF2 requires further experiments to explore.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of Tianjin Medical University General Hospital. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by the Ethics Committee of Tianjin Medical University General Hospital.

AUTHOR CONTRIBUTIONS

LY: Project development and manuscript editing; HX: Manuscript writing; YL: Data collection and analysis; RZ: Reviewed the manuscript. All authors contributed to the article.

REFERENCES

Cao, Y., Pan, L., Zhang, X., Guo, W., and Huang, D. (2020). LncRNA SNHG3 Promotes Autophagy-Induced Neuronal Cell Apoptosis by Acting as a ceRNA for miR-485 to Up-Regulate ATG7 Expression. Metab Brain Dis. 35, 1361–1369.
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., et al. (2012). The Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1. Cancer Discov. 2 (5), 401–404. doi:10.1158/2159-8290.CD-12-0095
Chang, K., Wang, G., Lou, J., Hao, S., Lv, R., Duan, D., et al. (2020). LncRNA TTN-AS1 Upregulates RUNX1 to Enhance Glioma Progression via Sponging miR-27b-3p. Oncol. Rep. 44 (3), 1064–1074. doi:10.3892/or.2020.7684
Chen, P., Wang, R., Yue, Q., and Hao, M. (2018). Long Non-coding RNA TTN-AS1 Promotes Cell Growth and Metastasis in Cervical Cancer via miR-573/E2F3. Biochem. Biophys. Res. Commun. 503 (4), 2956–2962. doi:10.1016/j.bbrc.2018.08.077
Chen, W., Yang, J., Fang, H., Li, L., and Sun, J. (2020). Relevance Function of Linc-ROR in the Pathogenesis of Cancer. Front. Cel Dev. Biol. 8, 696. doi:10.3389/fcell.2020.00696
Cui, Z., Luo, Z., Lin, Z., Shi, L., Hong, Y., and Yan, C. (2019). Long Non-coding RNA TTN-AS1 Facilitates Tumorigenesis of Papillary Thyroid Cancer through Modulating the miR-153-3p/ZNF222 axis. J. Gene Med. 21 (5), e3083. doi:10.1002/jgm.3083
Dong, M. M., Peng, S. J., Yuan, Y. N., and Luo, H. P. (2019). LncRNA TTN-AS1 Contributes to Gastric Cancer Progression by Acting as a Competing Endogenous RNA of miR-376b-3p. Neoplasma 66 (4), 564–575. doi:10.4149/neo_2018_180927N721
Frontiers in Genetics | www.frontiersin.org
October 2021 | Volume 12 | Article 704712
7
Feng, H., Wang, Q., Xiao, W., Zhang, B., Jin, Y., and Lu, H. (2020). LncRNA TTN-AS1 Regulates miR-324-5p and RMR2 to Promote Breast Cancer Progression. Curr. Top. Med. Chem. 20 (3), 481–487. doi:10.2174/15680266206662001146712

Qi, G., and Li, L. (2020). LncRNA TTN-AS1 Promotes Progression of Non-small Cell Lung Cancer via Regulating miR-491-5p/ZNF503 Axis. Oncotarget 11, 684242. doi:10.3389/fonc.2021.684242

Quan, J., Pan, X., Zhao, L., Li, Z., Dai, K., Yan, F., et al. (2018). LncRNA as a Diagnostic and Prognostic Biomarker in Bladder Cancer: A Systematic Review and Meta-Analysis. Oncotarget 11, 6415–6424. doi:10.2147/ott.s367853

Smirnov, I., Iasemidis, L., Papanicolaou, A., and Karavelis, A. (2018). Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Sci. Signal. 6 (269), pl1. doi:10.1126/scisignal.a243482

Gao, J., Aksoy, B. A., Dogrusoz, U., Dresden, G., Gross, B., Sumer, S. O., et al. (2013). Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Sci. Signal. 6 (269), pl1. doi:10.1126/scisignal.a243482

Hai, T., and Curran, T. (1991). Cross-family Dimerization of Transcription Factors Fox/Jun and ATF/CREB Alters DNA Binding Specificity. Proc. Natl. Acad. Sci. USA 88 (9), 3720–3724. doi:10.1073/pnas.88.9.3720

Hinsenfeld, F. J., Boorman, J. L., van der Poel, van der Schoot, D. K. E., Vis, A. N., and Aben, K. K. H. (2021). Intermediate-term Survival of Robot-Assisted versus Open Radical Cystectomy for Muscle-Invasive Non-muscle Invasive Bladder Cancer in The Netherlands. Urol Oncol. 51078-1439 (21), 00277. doi:10.1016/j.urolonc.2021.06.018

Inose, S., Mizushima, T., Ide, H., Jiang, G., Goto, T., Nagata, Y., et al. (2018). ATF2 Promotes Urothelial Cancer Outgrowth via Cooperation with Androgen Receptor Signaling. Endocr. Connect. 7 (12), 1397–1408. doi:10.1530/ec-18-0364

Li, Z., Hong, S., and Liu, Z. (2018). LncRNA LINC00641 Predicts Progression and Inhibits Bladder Cancer Progression through miR-197-3p/PTEN/PI3K/ AKT cascade. Biochem. Biophys. Res. Commun. 503 (3), 1825–1829. doi:10.1016/j.bbrc.2018.07.120

Li, Y., Shi, B., Dong, F., Zhu, X., Liu, B., and Liu, Y. (2020). LncRNA KCNQ1OT1 Facilitates the Progression of Bladder Cancer by Targeting MIR-218-5p/H19ST3B1 Cancer Gene Ther. 28 (3–4), 212–220. doi:10.1038/s41417-020-00211-6

Li, C., Cao, Y., Zhang, L., Li, J., Wu, H., Ling, F., et al. (2020). LncRNA IGFBP4-1 Promotes Tumor Development by Activating Janus Kinase-Signal Transducer and Activator of Transcription Pathway in Bladder Urothelial Carcinoma. Int. J. Biol. Sci. 16 (13), 2271–2282. doi:10.7150/ijbs.46986

Lin, C., Zhang, S., Wang, Y., Wang, Y., Nice, E., Guo, C., et al. (2018). Functional Role of a Novel Long Noncoding RNA TTN-AS1 in Esophageal Squamous Cell Carcinoma Progression and Metastasis. Clin. Cancer Res. 24 (2), 486–498. doi:10.1158/1078-0432.ccr-17-1851

Lin, K., Chen, H., Su, C., Zhu, H., Lai, C., and Shi, Y. (2020). Long Non-coding RNA TTN-AS1 Serves as a Competing Endogenous RNA of miR-195 to Facilitate Clear Cell Renal Cell Carcinoma Progression. Cmbr. Mol. Biol. 12, 3091–3097. doi:10.2147/cmbr.s249456

Liu, Y., Li, X., Zhang, C., Zhang, H., and Huang, Y. (2020). Involves in Cancer Immune Suppression through Positive Regulation of Siglec-15 in ccRCC. Cancer Sci. 111 (10), 3693–3704. doi:10.1111/cas.14611

Lopez-Bergami, P., Lau, E., and Ronai, Z. E. (2010). Emerging Roles of ATF2 and Activator of Transcription Pathway in Bladder Urothelial Carcinoma. J. Biol. Sci. 46, 600–607. doi:10.1002/biof.1622

Miao, S., Wang, J., Xuan, L., and Lu, X. (2020). LncRNA TTN-AS1 Acts as Sponge for miR-15b-5p to Regulate FBXW7 Expression in Ovarian Cancer. Biofactors, 46, 600–607. doi:10.1002/biof.1622

Peng, M., Cheng, X., Xiong, W., Yi, L., and Wang, Y. (2021). Integrated Analysis of a Competing Endogenous RNA Network Reveals a Prognostic IncRNA Signature in Bladder Cancer. Front. Oncol. 11, 684242. doi:10.3389/fonc.2021.684242

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Xiao, Huang, Li, Zhang and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.